01/09/23 8:30 AMNasdaq : ACER low floatAcer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 MilestonesNEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmetRHEA-AIneutral
01/05/23 8:30 AMNasdaq : ACER low floatAcer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the ProstateAcer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused onRHEA-AIneutral
12/29/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics Compliant with All Nasdaq Listing CriteriaAcer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that TheRHEA-AIneutral
12/27/22 8:30 AMNasdaq : ACER fda approvallow floatAcer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”)RHEA-AIpositive
11/30/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics Announces $1.5M Private PlacementAcer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that itRHEA-AIneutral
11/14/22 5:08 PMNasdaq : ACER earningslow floatAcer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate UpdateAcer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reportedRHEA-AIneutral
10/26/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition,RHEA-AIpositive
10/06/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate the potential for ACER-801 to reduce the frequency and severity of acute stress disorder andRHEA-AInegative
10/05/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress DisorderLicensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a distinct group of brain cells in a region of the brain that controls the formation andRHEA-AInegative
10/03/22 8:30 AMNasdaq : ACER low floatAcer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium BenzoateAcer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SARHEA-AIneutral